Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.92%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Updated

Inhibikase Therapeutics' Capital Leases came in at $58,330 for Q1 2024, down 67.3% from $178,110 a year earlier and down 35.3% from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024) Analysis & Trends

At the end of FY2023, Inhibikase Therapeutics' Capital Leases was $90,124, down 56.1% from FY2022.

  • Going back by year, Capital Leases was $205,451 in FY2022.
  • Year-over-year, Capital Leases has declined for three consecutive quarters.
  • Business Quant data shows IKT's Capital Leases at $90,124 (Q4 2023), $121,013 (Q3 2023) and $149,971 (Q2 2023) in the three quarters before Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 58,330.00
Dec 31, 2023 90,124.00
Sep 30, 2023 121,013.00
Jun 30, 2023 149,971.00
Mar 31, 2023 178,110.00
Dec 31, 2022 205,451.00
Sep 30, 2022 232,020.00
API Access

Inhibikase Therapeutics Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=IKT&period=max&api_key=YOUR_API_KEY